Two Cases of Acneiform Eruption Induced by Inhibitor of Epidermal Growth Factor Receptor
- 19 July 2007
- journal article
- case report
- Published by S. Karger AG in Skin Pharmacology and Physiology
- Vol. 20 (5), 260-262
- https://doi.org/10.1159/000106075
Abstract
Background: Cetuximab is a member of a new family of antineoplastic agents that inhibit the epidermal growth factor receptor (EGF-R), and which are increasingly being used in the treatment of solid tumors. Methods: We have observed new secondary side effects. We present here 2 patients with acneiform eruption secondary to the administration of cetuximab (IMC-C225, Erbitux). The diagnoses of these patients were adenocarcinoma. Results: Histologically, a superficial purulent folliculitis and disordered differentiation with focal parakeratosis were observed. The follicular eruption responded favorably to treatment with 5% benzoyl peroxide and 4% erythromycin gel. These lesions healed within a few days after treatment. Conclusion: The cutaneous adverse effects of cetuximab are similar to other EGF-R-targeted agents and result from direct interference with the functions of EGF-R signaling in the skin.Keywords
This publication has 10 references indexed in Scilit:
- An acneiform eruption due to erlotinib: Prognostic implications and managementJournal of the American Academy of Dermatology, 2006
- Cetuximab-Induced AcneDermatology, 2005
- Kinase Inhibitor-Induced PustulesDermatology, 2005
- Follicular Drug Eruption Induced by Gefitinib (ZD 1839, Iressa): Clinical Picture Correlates with in vitro Data of Focal Epidermal Necrosis after Epidermal Growth Factor Inhibition in Skin CulturesDermatology, 2005
- Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptorClinical and Experimental Dermatology, 2004
- Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancerThe Lancet Oncology, 2003
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptorBritish Journal of Dermatology, 2002
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Cutaneous Reactions to STI571New England Journal of Medicine, 2001
- Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225British Journal of Dermatology, 2001